HWM
IBRX icon

HighMark Wealth Management’s ImmunityBio IBRX Stock Holding History

HighMark Wealth Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-40
Closed -$79 – 572
2025
Q4 		$79 Hold
40
– – ﹤0.01% 576
2025
Q3 		$98 Hold
40
– – ﹤0.01% 599
2025
Q2 		$106 Hold
40
– – ﹤0.01% 604
2025
Q1 		$120 Hold
40
– – ﹤0.01% 558
2024
Q4 		$102 Hold
40
– – ﹤0.01% 561
2024
Q3 		$149 Hold
40
– – ﹤0.01% 570
2024
Q2 		$253 Buy
+40
New +$264 ﹤0.01% 558

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

HighMark Wealth Management's IBRX Position: Q1 2026 in Review

HighMark Wealth Management sold out of ImmunityBio (IBRX) in Q1 2026, closing a stake of 40 shares — an estimated $79 sold.

HighMark Wealth Management first reported a position in IBRX in Q2 2024 and held it in 7 quarters. The position peaked at $253 in Q2 2024. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • HighMark Wealth Management reported no remaining ImmunityBio position as of Q1 2026 after selling out during the quarter.
  • HighMark Wealth Management sold 40 ImmunityBio shares in Q1 2026, an estimated $79.
  • HighMark Wealth Management first reported a position in ImmunityBio in Q2 2024 and held it in 7 quarters.
  • HighMark Wealth Management's ImmunityBio position peaked at $253 in Q2 2024.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on HighMark Wealth Management's 13F filing for Q1 2026, filed 6 May 2026.